This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
hereditary-angioedema
Hereditary Angioedema
Hereditary angioedema (HAE) is recurrent bradykinin-mediated swelling from C1-INH deficiency; laryngeal HAE causes asphyxiation. Icatibant (B2R antagonist) and C1-INH concentrate for acute attacks; berotralstat and lanadelumab for long-term prophylaxis.
Entry Metadata
| Field | Value |
|---|---|
| ID | hereditary-angioedema |
| Name | Hereditary Angioedema |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541. · PubMed 20818873
- Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121. · PubMed 30480729
- Zuraw BL, Busse PJ, White M, et al. Berotralstat (BCX7353) for the prevention of hereditary angioedema. N Engl J Med. 2021;384(23):2186-2195. · PubMed 34077648